For decades, we have presumed the death of hair cells and spiral ganglion neurons are the main cause of hearing loss and difficulties understanding speech in noise, but new findings suggest synapse loss may be the key contributor. Specifically, recent preclinical studies suggest that the synapses between inner hair cells and spiral ganglion neurons with low spontaneous rates and high thresholds are the most vulnerable subcellular structures, with respect to insults during aging and noise exposure. This cochlear synaptopathy can be "hidden" because this synaptic loss can occur without permanent hearing threshold shifts. This new discovery of synaptic loss opens doors to new research directions. Here, we review a number of recent studies and make suggestions in two critical future research directions. First, based on solid evidence of cochlear synaptopathy in animal models, it is time to apply molecular approaches to identify the underlying molecular mechanisms; improved understanding is necessary for developing rational, effective therapies against this cochlear synaptopathy. Second, in human studies, the data supporting cochlear synaptopathy are indirect although rapid progress has been made. To fully identify changes in function that are directly related this hidden synaptic damage, we argue that a battery of tests including both electrophysiological and behavior tests should be combined for diagnosis of "hidden hearing loss" in clinical studies. This new approach may provide a direct link between cochlear synaptopathy and perceptual difficulties.
Introduction
Hearing loss is one of the most common chronic conditions. Two major types of hearing loss, noise-induced hearing loss (NIHL) and age-related hearing loss (ARHL), often coexist in the same ear.
Sensorineural hearing loss is one major diagnosis of both types of hearing loss, which was historically assumed due to loss of hair cells and spiral ganglion neurons (SGNs). For NIHL, a recent seminal discovery shows that synaptic loss between inner hair cells (IHCs) and SGNs is the primary pathology even with only temporary threshold shifts (TTS), and this synaptic loss is independent of both IHC and SGN loss (for review, Kujawa and Liberman, 2015) . For ARHL, Sergeyenko et al. (2013) shows a similar synaptic loss between IHCs and SGNs during aging, and our studies have shown that normal age-related loss of IHCs, outer hair cells (OHCs), SGNs, and cochlear synapses between OHCs and medial olivocochlear efferent fibers can incur independently (Fu et al., 2010; Jin et al., 2011) . Therefore, the synaptic connection between IHCs and SGNs may be the most vulnerable cochlear structure to aging or noiseinduced damages, a key pathology for sensorineural hearing loss.
Although there are other types of synapses in the cochlea, the term cochlear synaptopathy is used here to specifically refer to synaptic loss between the IHC and SGN.
There are two types of SGN afferent fibers carry auditory information from hair cells to the central auditory system: type I and II SGNs. The type II SGNs, only about 5% of total SGNs, make synapses with outer hair cells (OHCs) in the cochlea. The type I SGNs, making synapses with IHCs, can be further subdivided into three functional groups based on their spontaneous discharge rates (SR) and dynamic range. High-SR SGNs, making up 60% of all type I SGNs, have low thresholds and wide dynamic ranges. Low-SR SGNs have high thresholds and wide dynamic ranges, and medium-SR SGNs have both thresholds and dynamic ranges intermediate to high and low-SR SGNs. Several anatomical differences are associated with these differences in spontaneous rate and dynamic range. High-SR fibers have thicker axons, more mitochondria, and synapses on the pillar side, while low-and medium-SR fibers have thinner axons, fewer mitochondria, and tend to synapse on the modiolar side of the IHC (Liberman and Kiang, 1978, 1984; Liberman, 1988) . In addition, there are compelling differences in receptor patch characteristics . Each IHC is innervated by multiple type I SGNs, but each SGN contacts only a single IHC. At each synapse, an electron-dense ribbon is located at a pre-synaptic region normally surrounded by a halo of synaptic vesicles containing glutamate (for review, Fuchs et al., 2003; Moser and Starr, 2016) . The sound-induced fluid vibration deflects IHC stereocilia and causes the activation of mechanoelectric transduction channels, and the resulting potassium (Kþ) cation influx generates a depolarizing receptor potential. This graded potential triggers calcium (Ca 2þ ) influx through voltage-gated Ca 2þ channels at the presynaptic active zones of the ribbon synapse, driving synaptic vesicle fusion and glutamate release (Fuchs, 2005) . Thus, rather than transmitting a binary action potential code, this synapse encodes a graded presynaptic signal into a rate coded stimulation of the SGN. Most recent literatures have used the term disruption of "low-SR SGNs" to distinguish loss of the two lower-SR classes of neurons from the unaffected high-SR fibers. To be consistent, we also use the term of "low-SR SGNs" to include both medium-and low-SR SGNs. The seminal discovery of cochlear synaptopathy was initially made in CBA/CaJ mice Liberman, 2006, 2009) . In these animals, up to half of their IHC/SGN synapses were lost after noise exposure, despite a full recovery of their hearing thresholds measured by the auditory brainstem response (ABR). This finding was confirmed in subsequent studies Wang and Ren, 2012; Furman et al., 2013; Hickox and Liberman, 2014; Fernandez et al., 2015; Jensen et al., 2015) . For those noise conditions resulting in synapse pathology, a significant permanent decrease in the supra-threshold growth of ABR wave I amplitude was observed despite a full recovery of otoacoustic emission (OAE) amplitudes and ABR thresholds . These two latter conditions are critical in that they indicate that OHCs, IHCs and high-SR SGNs ultimately return to pre-noise baseline (i.e., normal) levels of function. The presence of intact high-SR neurons is suggested by the intact threshold response, and the functional indication of the high-SR SGN preservation is supported directly by shifts in modiolar-pillar synapse ratios in the region of maximum synaptopathy in the mouse , where most synapses made by the low-SR SGNs are located closer to the spiral ganglion (modiolar area). This type of selective cochlear synaptopathy has been also termed "hidden hearing loss" because supra-threshold functional deficits are assumed to be "hidden" behind the normal ABR thresholds (Schaette and McAlpine, 2011; Kujawa and Liberman, 2015) . The hypothesized supra-threshold deficits seem reasonable to infer based on changes in suprathreshold function with massive IHC loss (Lobarinas et al., 2016) and the pattern of changes observed in patients diagnosed with auditory neuropathy (which may occur anywhere in the ascending auditory pathway (for review, see Le Prell and Lobarinas, 2015) .
It has been known for many years that conventional pure-tone audiograms do not necessarily predict performance on suprathreshold auditory perception tasks. For example, difficulties understanding speech-in-noise are observed in older adults with normal audiometric thresholds (e.g. Carhart and Tillman, 1970; Dubno et al., 1997 ; Working Group on Speech Understanding, Committee on Hearing, Bioacoustics, and Biomechanics, 1988; Frisina and Frisina, 1997; Tremblay et al., 2015) ; younger listeners with significant noise exposure histories but little overt hearing threshold shift can also experience relatively poorer cochlear function (Kumar et al., 2012; Hope et al., 2013) . Loss of fidelity in the encoding of supra-threshold signals due to selective cochlear synaptopathy of low-SR SGN fibers may provide the explanation for "hidden hearing loss." However, it is difficult to directly diagnose human cochlear synaptopathy and its subsequent functional deficit as post-mortem tissue assessment is necessary to document synaptic status (e.g., Viana et al., 2015) . In animal studies, the direct evidence for cochlear synaptopathy comes from the synaptic quantification by immunocytochemical method. The current clinical strategies for monitoring noise injury in humans are still based on the audiogram, i.e., behaviorally determined pure-tone thresholds in quiet (as required by OSHA, 1983; NIOSH, 1998) ; however, there is increasing interest in speech-in-noise testing for use in clinical trials (for recent reviews, Le Prell and Lobarinas, 2015; Le Prell and Brungart, 2016) Miller et al., 2004; KonradMartin et al., 2012; Seixas et al., 2012) , but these are not required as part of current occupational health monitoring programs. One major complication with efforts to apply the current data linking acute TTS to reassessment of the federal hearing conservation regulations is that it is not yet known if occupational noise exposures will result in "hidden hearing loss", as the acute TTS changes associated with cochlear synaptopathy in animal models are not typical for workers at OSHA-regulated job sites. The limited data currently available for very long low level exposures or repeat exposures have yielded mixed outcomes (Maison et al., 2013; Gannouni et al., 2015; Mannstrom et al., 2015) . In addition, recent data supporting the presence of "hidden hearing loss" in humans all come from cross-section observations (comparisons at a single point in time) instead of longitudinal approaches (comparisons over time, most for the same individual) similar to animal studies (Stamper and Johnson, 2015a,b; Bramhall et al., 2017; Liberman et al., 2016) . Thus, although preclinical data clearly challenge the long-held belief that noise exposures resulting in TTS are by definition benign, human data that would support evidence-based damage-risk criteria are not conclusive. For future clinical studies, since human functional assays are highly variable and direct histological methods are very difficult if not impossible, improved evoked potential methods sensitive to, and specific to, "hidden hearing loss" need to be developed. Such tools in combination with other methods are necessary to lead to the identification of a reliable association between inferred cochlear synaptopathy and specific auditory perception deficits (Bharawaj et al., 2014; Kujawa and Liberman, 2015; Shaheen et al., 2015) .
Critical issues to be addressed by preclinical studies

Mechanisms for cochlear synaptopathy
This new discovery of cochlear synaptopathy opens doors to new research directions. The detailed pathologic and molecular cascades of cochlear synaptopathy cannot be resolved in humans; thus, these must be addressed in animal models. Interestingly, based on different noise exposure levels and durations, acute noise exposures can induce TTS with or without cochlear synaptopathy (Fernandez et al., 2015; Furman et al., 2013; Hickox and Liberman, 2014; Jensen et al., 2015; Yu et al., 2016) . In general, it appears that if the most affected frequency has TTS of 40e50 dB 24 h after the noise exposure ends, synaptopathy and changes in supra-threshold wave I amplitude persist, whereas if the most affected frequency has TTS of 30 dB or less 24 h after the exposure ends, there is no evidence of synaptopathy or decrease in ABR wave I amplitude (Fernandez et al., 2015; Jensen et al., 2015) . These two types of "TTS only" phenotypes provide ideal models in which molecular cascades involved in cochlear synaptopathy can be dissected. In the absence of cochlear synaptopathy, TTS deficits are presumably a consequence of reversible stereocilia damage, hair cell metabolic dysfunction, synaptic terminal swelling, conduction block, or other reversible un-identified damages (e.g., Hu, 2012; Kujawa and Liberman, 2015; Wang et al., 2002) . When the noise insult increases such that cochlear synaptopathy is induced, this synaptopathy is presumably added on top of these other reversible injuries; such issues are well suited for current molecular approaches such as gene array methods (e.g., Taggart et al., 2001 ).
An alternative approach that might be considered for new mechanistic studies is to focus on candidate pathways already implicated in noise-induced pathology (for reviews, Abi , 2007) . Although most of these pathways have not been investigated with respect to a potential role in synaptopathy, both glutamate excitotoxicity and calcium signaling pathways are promising candidate pathways. Studies in vitro show that excess glutamate leads to synaptic loss between IHCs and SGNs (Wang and Green, 2011) . Toxic concentrations of this excitatory neurotransmitter lead to large calcium, sodium and potassium ion flux into SGNs which in turn may produce swelling, and ultimately rupturing of postsynaptic structures (Puel et al., 1994 (Puel et al., , 1998 Le Prell et al., 2004) . Based on the expression of ion channels permeable to calcium in SGNs, both L-type and T-type calcium channels could contribute to this excess calcium after noise trauma, and our recent studies have implicated T-type calcium channels as playing an important role in NIHL (Bao et al., 2013; Kopecky et al., 2014) . Besides excessive calcium influx in postsynaptic terminals, another consequence of noise exposure is an increase of calcium in hair cells (Glowatzki et al., 2008) , which could lead to a further calcium release from intracellular storages. The excess calcium increase could lead to not only excessive release of glutamate to damage postsynaptic structures, but also activations of down-stream calcium dependent pathways such as calcium/calmodulin-dependent protein phosphatase, which in turn activates mitochondriamediated cell death pathways (Oishi and Schacht, 2011) . Determinations of the exact roles of these pathways in cochlear synaptopathy can not only contribute to our understanding of this pathology, but also provide a solid basis to develop new therapies for NIHL.
Development of prevention and therapy methods
If pre-clinical studies on mechanisms of synaptopathology reveal a role for glutamate excitotoxicity, regulation of glutamate excitotoxicity might prevent noise-induced cochlear synaptopathy. There is a robust literature on glutamate as a cochlear neurotransmitter, glutamate receptor subtypes in the cochlea, glutamate excitotoxicity, and the use of specific glutamate receptor antagonists to attenuate injury (for recent review, Le Prell and Bao, 2012) . In brief, application of AMPA/KA or NMDA glutamate receptor blockers such as kynurenate and DNQX can reduce SGN dendritic damage (Puel et al., 1994 (Puel et al., , 1998 . Similarly, MK-801, an antagonist for the NMDA subtype of glutamate receptor, can protect against NIHL, although it is not known whether this protection is due to a preservation of synapses between IHCs and SGNs or other mechanisms of action (Ohinata et al., 2003) . Therefore, detailed pharmacodynamics studies with current immunohistological methods are needed to determine whether a modulation of glutamate excitotoxicity pathways could prevent cochlear synaptopathy. A down-regulation of calcium signaling pathways could be another protective approach. Our recent studies showed that blockers for Ttype voltage-gated calcium channels are effective against NIHL, and NIHL can also be prevented by blockers for L-type voltage-gated calcium channels (Heinrich et al., 1999; Uemaetomari et al., 2009) , although these studies similarly did not focus on cochlear synaptopathy.
Neurotrophins have also shown promise in preventing NIHL. Glial cell line-derived neurotrophic factor (GDNF) provides protection in a dose-dependent manner, and its efficacy may reside in its ability to modulate calcium signaling, or even to reduce free radical generation (Shoji et al., 2000) . Most importantly, since neurotrophins are critical for cochlear synaptic formation during development (for review, Fritzsch et al., 2004) , recent studies in vitro (Wang and Green, 2011; Green et al., 2012) and in vivo (Stankovic et al., 2004; Wan et al., 2014) show that neurotrophins such as NT-3 and BDNF may be able to rescue synaptopathy by promoting synaptic regeneration (for recent reviews, see Kujawa and Liberman, 2015) .
Critical issues to be addressed by clinical studies
It would be highly significant to confirm the existence of "hidden hearing loss" in human populations, and this evidence could be used to guide proposals for changes in federal guidelines if relationships in which noise exposure-induced declines were documented. The extent to which such efforts will ultimately be successful seems likely to be influenced by how reliable and sensitive the detection methods are. Because the combination of electrophysiological and immunohistological methods from animal studies is difficult (if not impossible) to apply to human studies, we foresee that one major theme in this field is to develop reliable and minimally invasive tools that allow reasonable inferences about the degree of synaptic damage when interpreted as part of a comprehensive test battery. These tools can be considered suitable for the diagnosis of human cochlear synaptopathy only when their outcomes are dominated by cochlear synaptopathy. Due to the limitation of current technologies, we argue that if a strong link is established for the diagnosis outcomes between the direct detection methods (e.g., electrophysiological testing such as ABR wave I) and indirect detection methods (e.g., behavior testing such as speech-in-noise tests), a test battery including both types of these tests would be justified for the clinical diagnosis of cochlear synaptopathy, when used in combination with a traditional battery including otoscopy and immittance to assess the outer and middle ear, and DPOAEs to infer the health of the OHC population. Decreased amplitude of the OAEs, and the presence of overt threshold shift, do not preclude the presence of a synaptic loss or other neural pathology, but they will complicate the interpretation of the extent to which observed functional deficits are related to synaptic or ascending neural loss, rather than the compromised OHC status.
Electrophysiological approaches
Sound-evoked electrophysiological auditory responses such as the ABR and auditory subcortical steady-state responses (SSSRs) have been used to detect a potential cochlear synaptopathy in humans (for recent reviews, Bharadwaj et al., 2014; Plack et al., 2016) . ABR tests are routinely used in the clinic. However, ABR wave I amplitude varies as a function of sex as well as the stimulation and recording parameters, therefore, ABR latency is frequently utilized in clinical assessment. A significant association in which ABR wave I amplitude decreased with increasing noise exposure history was reported for a population of "normal" hearing listeners (10 male, 20 female) who self-reported their recreational noise exposure over the previous one-year period (Stamper and Johnson, 2015a) . Those data were later re-analyzed to correct for a potential confounding relationship with gender, as males have smaller average response amplitudes and longer average response latencies than females (possibly due to differences in head size with electrode placements being more distal to the generator site in males than in females). After adjusting for sex, the reported decrease in ABR amplitude with increasing noise exposure was found only in females (Stamper and Johnson, 2015b) . In a recently completed PhD thesis (Fulbright, 2016 ; University of Florida) with a larger sample size (26 males, 34 females), there were no reliable relationships between ABR amplitude and noise history, or ABR amplitude and performance on speech-in-noise tests, with recreational noise exposure generally being similar to that described by Stamper and Johnson (2015a, b) . Preliminary data reported by Prendergast et al. (2016) confirm and extend these observations in 129 normal hearing listeners, with not only the failure to detect a relationship between ABR amplitude and noise history, but also a failure to detect relationships between temporal listening tasks and noise exposure, and speech-in-noise tasks and noise exposure.
In contrast to these results in subjects with a variety of recreational exposures, new auditory symptoms were widely reported after blast exposure in a civilian population (Remenschneider et al., 2014) , and such symptoms are well identified in military personnel after blast exposure (Saunders et al., 2015; Gallun et al., 2012a,b; Helfer et al., 2011;  for review see Gallun et al., 2012a,b) . Systematic decreases of ABR wave I amplitude, with and without changes in later waves, have also been seen in those with tinnitus (Gu et al., 2012; Schaette and McAlpine, 2011) . Recently, Liberman et al. (2016) have taken two steps to detect possible cochlear synaptopathy in human subjects with low-and high-risk of noise exposure. These included (1) using electrocochleography (EcochG) to measure click-evoked ABRs using "tiptrodes" within the ear canal, with recording parameters that permitted measurement of the presynaptic summating potential (SP) generated by hair cells; (2) using the ratio between the SP waveform peaks and ABR wave I amplitude to reduce the variability of ABR wave I amplitudes. Both the low-and high-risk groups had normal hearing thresholds, but the high-risk group had a significantly larger AP/SP ratio, with the group difference largely driven by an increase in the amplitude of the summating potential in the students in the music program. This higher-risk music-exposed group also showed significantly poorer performance on word recognition in noise, including conditions with time compression and reverberation, and they had significantly poorer thresholds at extended high frequencies (10 kHz and above). This findings have been confirmed by Bramhall et al. (2015 Bramhall et al. ( , 2017 with similar approaches. These observations are intriguing, and additional research is necessary to confirm these findings in longitudinal studies similar to previous animal studies. Technically, a high variability in the AP/SP ratio must be further addressed. One strategy may be to measure the latency of human ABR wave V under masking noise (Mehraei et al., 2016) , as the effect of masking noise on the latency of ABR wave V appears to be correlated with changes of the amplitude of ABR wave I.
To be considered in the development of a clinical ABR-based diagnostic test for "hidden hearing loss," Le Prell and Lobarinas (2015) raise a host of questions for current approaches. Specifically, they note that new normative databases are needed in order to identify whether a given individual's ABR response is normal or decreased in amplitude. In addition, they note the importance of determining what parameters would trigger a diagnosis of decreased amplitude (hidden hearing loss), and what would constitute clinically significant improvement if a therapeutic were to be assessed. Also important, they query the boundary at which an "atypical" amplitude (or ratio of amplitudes) would begin. In other words, how different must an individual response be from the group normative data to be defined as atypical? Based on these considerations, a longitudinal design of human studies would be ideal because it would allow for comparison between pre-and post-noise exposure auditory responses in the same ear. In addition, a combination of multiple different methods to detect cochlear synaptopathy for the same individual would diminish possible false positive or negative outcomes from one specific test . Therefore, additional testing beyond the ABR would be helpful for the detection of cochlear synaptopathy.
Periodic evoked potentials to amplitude-modulated sounds originating from both the cortical and sub-cortical regions of the central auditory nervous system are often referred to as auditory steady-state responses (ASSRs). ASSR has traditionally been used to confirm elevated behavioral thresholds, as opposed to the now proposed use as a more sensitive metric for detection of deficits at supra-threshold sound levels (Hsu et al., 2010 (Hsu et al., , 2011 Attias et al., 2014; Karawani et al., 2015) . Attias et al. (2014) reported a steeper slope of the ASSR growth rates for workers with NIHL compared to normal hearing listeners, but listeners with NIHL are distinct from workers with a "hidden hearing loss" as hidden hearing loss by definition excludes anyone with overt threshold shift. Correlations between ASSR modulation detection threshold and speech-innoise test outcomes have been reported (Manju et al., 2014) , which warrant further investigation with respect to mediation of both metrics by noise history. The evoked potentials with subcortical origin are specifically referred as SSSRs, which can be distinguished from the cortical responses by virtue of their relatively high frequency content (Krishnan et al., 2012; Bharadwaj et al., 2014) . Recently, SSSRs are most commonly referred to as envelope following responses (EFRs) or frequency following responses (FFRs), which reflect synchronized neural activity in the brainstem to the waveform of the sound stimulus (Krishnan et al., 2012) . The FFR reflects phase locking to temporal fine structure for frequencies up to about 1 kHz and is particularly sensitive to amplitude modulation (at the rates of a few hundred hertz). Cochlear synaptopathy is selective for low-SR SGN fibers with high thresholds, and phase locking to temporal envelopes is particularly strong in these fibers, thus, it is not surprising to find that the EFR or FFR is more sensitive for cochlear synaptopathy in both animal and human studies (Bharadwaj et al., 2014; Shaheen et al., 2015) . Because, based on the modulation frequencies, FFR can be influenced from various central auditory regions such as the inferior colliculus (Krishnan et al., 2012) , differences in central auditory processing may contribute to individual differences in FFR amplitude. For example, it is known that musicians and tone language speakers have a stronger FFRs for certain auditory stimuli (Krishnan et al., 2005 (Krishnan et al., , 2012 . Thus, similar to the ABR, the variability is also an issue for FFR approaches, which argue a combination of both approaches for the diagnosis of cochlear synaptopathy.
Behavioral approaches
A direct link between cochlear synaptopathy and behavioral performance is difficult to establish because outcomes of most behavioral tests of suprathreshold perception are influenced by many other factors, such as cognitive skill, memory, and contextual cues. Despite these challenges, there has been rapid progress. The logic underlying recent hypotheses is two-fold. First, based on the response properties of low-SR SGNs, behavioral tests of temporal processing ability should be sensitive to cochlear synaptopathy. Second, if a link is found for the outcomes between selected behavioral tests of suprathreshold perception and more direct measurements of cochlear synaptopathy (such as ABR wave I amplitude, AP/SP ratio, ASSR, or other metrics), it would suggest the behavioral perceptual test is appropriate to include in the test battery for cochlear synaptopathy.
It has been suggested that ABR wave I amplitude decreases will likely be accompanied by decreased ability to understand speech, especially in noisy environments Liberman, 2006, 2009; , as well as diminished auditory temporal processing ability (Bharadwaj et al., 2014; Shaheen et al., 2015) . A variety of speech-in-noise test protocols are available (for reviews, see Le Prell and Lobarinas, 2015; Le Prell and Brungart, 2016) . NIHL has been found to be associated with poorer function on speech-innoise tasks, which could be related to either audibility or to distortion of the target signal (Jansen et al., 2014; Leensen et al., 2011a Leensen et al., , 2011b Smoorenburg, 1992) . In a recent detailed review of the literature on this topic, Le Prell and Clavier (2016) describe a growing number of studies in which small but statistically significant differences are observed, even though both the control and the noise-exposed subject groups have thresholds that are within normal limits (i.e., up to 25 dB HL). In other studies, no data are provided for the two groups; the extent of the information provided is that all subjects were within normal limits. The variety of studies in which deficits are reported for those exposed to noise is compelling (e.g., Alvord, 1983; Kujala et al., 2004; Stone et al., 2008; Kumar et al., 2012; Hope et al., 2013; Stone and Moore, 2014; Liberman et al., 2016) , although caution is warranted given the potential that there were systematic differences in threshold sensitivity or unidentified differences in OHC integrity. Recently, based on a combination of different approaches including electrophysiological methods (EcochG and EFR) and behavioral testing, such as interaural time difference discrimination task and understanding of speech-in-noise with time compression and reverberant backgrounds (e.g., Bharadwaj et al., 2014; Liberman et al., 2016) , the evidence for an association between cochlear synaptopathy and suprathreshold hearing status continues to grow. These systematic combination approaches raise hope that a new diagnostic battery for cochlear synaptopathy can be successfully developed.
Summary
Based on the pre-clinical literature to date, both direct and indirect evidence for cochlear synaptopathy suggests a plausible testable hypothesis that is likely to explain clinical reports of difficulties in adverse listening situations despite pure tone thresholds within normal limits. Currently there are a number of informational gaps that limit our approach to interrogating the validity of the hypothesis, both at the pre-clinical and clinical levels. In pre-clinical models, it is critical to identify molecular cascades underlying cochlear synaptopathy, which is vital for establishing molecular cascades or markers for this newly discovered pathology and developing future interventions. At the clinical level, it is important to validate a combination approach for identifying clinically meaningful perceptual consequences dominated by cochlear synaptopathy.
From a public health perspective, there is a need to raise general consciousness about the potential long-term consequences of noise on hearing, and there is a need to educate and motivate individuals to protect their hearing. From a scientific perspective, there is an urgent need for new objective measures of treatment efficacy for various clinical trials of hearing loss such that suprathreshold function can be assessed in a standardized way and potentially even used to infer function of specific cellular structures when interpreted as part of a test battery.
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